Io Biotech Stock Analysis

IOBT Stock Analysis Notes

About 48.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 1.34. IO Biotech had not issued any dividends in recent years. IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating cancer therapies based on the T-win technology platform. The company was incorporated in 2014 and is based in Copenhagen, Denmark. Io Biotech operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 32 people. To learn more about IO Biotech call the company at 45 70 70 29 80 or check out https://www.iobiotech.com.

IO Biotech Investment Alerts

IO Biotech Upcoming and Recent Events

IOBT Largest EPS Surprises

View All Earnings Estimates

IOBT Stock Institutional Investors

Note, although IO Biotech's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

IOBT Market Capitalization

The company currently falls under 'Micro-Cap' category with a current market capitalization of 48.28 M.

IOBT Profitablity

Management Efficiency

IO Biotech has return on total asset (ROA) of (0.8858) % which means that it has lost $0.8858 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.4048) %, meaning that it created substantial loss on money invested by shareholders. IO Biotech's management efficiency ratios could be used to measure how well IO Biotech manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -1.33 in 2026. Return On Capital Employed is likely to gain to -2.16 in 2026. At this time, IO Biotech's Liabilities And Stockholders Equity is comparatively stable compared to the past year. Non Current Liabilities Other is likely to gain to about 2.7 M in 2026, whereas Total Current Liabilities is likely to drop slightly above 12.8 M in 2026.

Technical Drivers

As of the 6th of January, IO Biotech owns the Market Risk Adjusted Performance of 1.8, semi deviation of 7.57, and Standard Deviation of 9.82. IO Biotech technical analysis makes it possible for you to employ past data patterns with the intention to determine a pattern that calculates the direction of the firm's future prices.

IO Biotech Price Movement Analysis

IO Biotech Insider Trading Activities

IO Biotech Outstanding Bonds

IO Biotech Predictive Daily Indicators

IO Biotech Forecast Models

IO Biotech's time-series forecasting models are one of many IO Biotech's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary IO Biotech's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

IO Biotech Bond Ratings

IO Biotech financial ratings play a critical role in determining how much IO Biotech have to pay to access credit markets, i.e., the amount of interest on their issued debt. The threshold between investment-grade and speculative-grade ratings has important market implications for IO Biotech's borrowing costs.

IO Biotech Debt to Cash Allocation

IO Biotech currently holds 1.92 M in liabilities with Debt to Equity (D/E) ratio of 0.01, which may suggest the company is not taking enough advantage from borrowing. IO Biotech has a current ratio of 20.52, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about IO Biotech's use of debt, we should always consider it together with its cash and equity.

IO Biotech Total Assets Over Time

IO Biotech Assets Financed by Debt

The debt-to-assets ratio shows the degree to which IO Biotech uses debt to finance its assets. It includes both long-term and short-term borrowings maturing within one year. It also includes both tangible and intangible assets, such as goodwill.

IO Biotech Debt Ratio

3.09

It appears most of the IO Biotech's assets are financed through equity. Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the IO Biotech's operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of IO Biotech, which in turn will lower the firm's financial flexibility.

IO Biotech Corporate Bonds Issued

IOBT Short Long Term Debt Total

Stock analysis is the technique used by a trader or investor to examine and evaluate how IO Biotech prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling IOBT shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as IO Biotech. By using and applying IOBT Stock analysis, traders can create a robust methodology for identifying IOBT entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. IOBT analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. IOBT analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

IO Biotech stock analysis indicators help investors evaluate how IO Biotech stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading IO Biotech shares will generate the highest return on investment. By understating and applying IO Biotech stock analysis, traders can identify IO Biotech position entry and exit signals to maximize returns.

When running IO Biotech's price analysis, check to measure IO Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy IO Biotech is operating at the current time. Most of IO Biotech's value examination focuses on studying past and present price action to predict the probability of IO Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move IO Biotech's price. Additionally, you may evaluate how the addition of IO Biotech to your portfolios can decrease your overall portfolio volatility.